3.120PLN+1.63%Mkt Cap: 8.80M $P/E: —10d ago
Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. The company also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, it is involved…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
| Headline | Source | Time |
|---|---|---|
Older | ||
CCEO Magazyn | ||
BBIZNES24 | ||
SStrefa Inwestorów | ||
SStrefa Inwestorów | ||
BBIZNES24 | ||
SStrefa Inwestorów | ||
European Penny Stocks Under €800M Market Cap: Top 3 Picks To Consider The European market has shown resilience, with the pan-European STOXX Europe 600 Index ending 0.77% higher, supported by robust economic data and earnings results. For investors willing to explore beyond well-known names, penny stocks—often smaller or newer companies—can present intriguing opportunities. While the term might seem outdated, these stocks can offer a mix of affordability and growth potential when backed by strong financials. | ||